Regulation of cell function by isoform of C-reactive protein: A comparative analysis

• Autorzy: Boncler M. , Watala C.
• Języki publikacji: EN

Abstrakty

EN

 Despite the emerging evidence suggesting a proatherogenic role of C-reactive protein (CRP) in atherosclerosis, the contribution of CRP in pathogenesis of atherosclerosis and atherothrombosis has not been unequivocally defined. The role of CRP in pathophysiology/pathology seems to largely depend on its structure. Two CRP isoforms, the native pentameric and the modified monomeric one, differ substantially in their physiological functions, which is thought to origin from the considerable structural heterogeneity of the CRP molecule. The present review provides an overview of the experimental evidence with relevance to the clinical role(s) of various CRP isoforms. The biological role of the protein, its structure and distribution are discussed with particular emphasis on the diverse properties of the pentameric and monomeric forms of CRP. Some methodological aspects, related to experimental models and techniques of CRP preparation, are also critically reviewed.

Słowa kluczowe

EN

protein; protein distribution; atherosclerosis; biological role; pathogenesis; protein structure; C-reactive protein; cellular function; inflammation; regulation; isoform

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2009
• Tom: 56
• Numer: 1
• Opis fizyczny: p.17-31,ref.

Twórcy

autor

Boncler M.

• Medical University of Lodz, Medical University Hospital, No.2, Zeromskiego 113, 90-549 Lodz, Poland

autor

Watala C.

Bibliografia

• Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE (2001) Topology and structure of the C1q-binding site on C-reactive protein. J Immunol 166: 3998-4004.
• Agrawal A, Simpson MJ, Black S, Carey MP, Samols D (2002) A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide. J Immunol 169: 3217-3222.
• Agrawal A, Volanakis JE (1994) Probing the C1q-binding site on human C-reactive protein by site-directed mutagenesis. J Immunol 152: 5404-5410.
• Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM (2002) Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 105: 2595-2599.
• Ballou SP, Lozanski G (1992) Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 4: 361-368.
• Bang R, Marnell L, Mold C, Stein MP, Clos KT, Chivington-Buck C, Clos TW (2005) Analysis of binding sites in human C-reactive protein for FcγRI, FcγRIIA, and C1q by site-directed mutagenesis. J Biol Chem 280: 25095-25102.
• Bello G, Cailotto F, Hanriot D, Kolopp-Sarda MN, Latger-Cannard V, Hess K, Zannad F, Longrois D, Ropars A (2008) C-reactive protein (CRP) increases VEGF-A expression in monocytic cells via a PI3-kinase and ERK 1/2 signaling dependent pathway. Atherosclerosis 200: 286-293.
• Bhakdi S, Torzewski M, Klouche M, Hemmes M (1999) Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 19: 2348-2354.
• Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW (1999) The major receptor for C-reactive protein on leukocytes is Fcγ receptor II. J Exp Med 190: 585-590.
• Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A (1999) Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99: 855-860.
• Biro A, Rovo Z, Papp D, Cervenak L, Varga L, Fust G, Thielens NM, Arlaud GJ, Prohaszka Z (2007) Studies on the interactions between C-reactive protein and complement proteins. Immunology 121: 40-50.
• Bis JC, Heckbert SR, Smith NL, Reiner AP, Rice K, Lumley T, Hindorff LA, Marciante KD, Enquobahrie DA, Monks SA, Psaty BM (2008) Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke. Atherosclerosis 198: 166-173.
• Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den BB, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES (2005) Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 96: 714-716.
• Bisoendial RJ, Kastelein JJ, Peters SL, Levels JH, Birjmohun R, Rotmans JI, Hartman D, Meijers JC, Levi M, Stroes ES (2007) Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J Lipid Res 48: 952-960.
• Blake GJ, Ridker PM (2002) C-reactive protein and prognosis after percutaneous coronary intervention. Eur Heart J 23: 923-925.
• Boguslawski G, McGlynn PW, Potempa LA, Filep JG, Labarrere CA (2007) Conduct unbecoming: C-reactive protein interactions with a broad range of protein molecules. J Heart Lung Transplant 26: 705-713.
• Boncler M, Luzak B, Rozalski M, Golanski J, Rychlik B, Watala C (2006) Acetylsalicylic acid is compounding to antiplatelet effect of C-reactive protein. Thromb Res 119: 209-216.
• Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D (1996) Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 97: 1715-1722.
• Calabro P, Willerson JT, Yeh ET (2003) Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108: 1930-1932.
• Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM (1993) C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82: 513-520.
• Chang MK, Binder CJ, Torzewski M, Witztum JL (2002) C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 99: 13043-13048.
• Chang JW, Kim CS, Kim SB, Park SK, Park JS, Lee SK (2005) C-reactive protein induces NF-κB activation through intracellular calcium and ROS in human mesangial cells. Nephron Exp Nephrol 101: e165-e172.
• Ciubotaru I, Potempa LA, Wander RC (2005) Production of modified C-reactive protein in U937-derived macrophages. Exp Biol Med (Maywood) 230: 762-770.
• Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER (2003) Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 108: 512-515.
• Danenberg HD, Kantak N, Grad E, Swaminathan RV, Lotan C, Edelman ER (2007) C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy. Eur J Haematol 78: 246-252.
• Dasu MR, Devaraj S, Du Clos TW, Jialal I (2007) The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res 48: 509-512.
• De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA (2000) The transcription factor NF-κB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 20: E83-E88.
• Devaraj S, Xu DY, Jialal I (2003) C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107: 398-404.
• Devaraj S, Kumaresan PR, Jialal I (2004) Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 36: 405-410.
• Devaraj S, Du Clos TW, Jialal I (2005) Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 25: 1359-1363.
• Devaraj S, Venugopal S, Jialal I (2006) Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis 184: 48-52.
• Diehl EE, Haines GK III, Radosevich JA, Potempa LA (2000) Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 319: 79-83.
• Du Clos TW (1989) C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J Immunol 143: 2553-2559.
• Du Clos TW (2000) Function of C-reactive protein. Ann Med 32: 274-278.
• Duncan AR, Winter G (1988) The binding site for C1q on IgG. Nature 332: 738-740.
• Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ, Blundell TL, Pepys MB, Wood SP (1994) Structure of pentameric human serum amyloid P component. Nature 367: 338-345.
• Fiedel BA, Gewurz H (1976a) Effects of C-reactive protein on platelet function. I. Inhibition of platelet aggregation and release reactions. J Immunol 116: 1289-1294.
• Fiedel BA, Gewurz H (1976b) Effects of C-reactive protein on platelet function. II. Inhibition by CRP of platelet reactivities stimulated by poly-L-lysine, ADP, epinephrine, and collagen. J Immunol 117: 1073-1078.
• Fiedel BA, Simpson RM, Gewurz H (1977) Effects of C-reactive protein on platelet function. III. The role of cAMP, contractile elements, and prostaglandin metabolism in CRP-induced inhibition of platelet aggregation and secretion. J Immunol 119: 877-882.
• Fiedel BA, Simpson RM, Gewurz H (1982) Activation of platelets by modified C-reactive protein. Immunology 45: 439-447.
• Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454.
• Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G (1989) Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 8: 3773-3779.
• Garlanda C, Bottazzi B, Bastone A, Mantovani A (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23: 337-366.
• Gershov D, Kim S, Brot N, Elkon KB (2000) C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192: 1353-1364.
• Gewurz H, Mold C, Siegel J, Fiedel B (1982) C-reactive protein and the acute phase response. Adv Intern Med 27: 345-372.
• Hanriot D, Bello G, Ropars A, Seguin-Devaux C, Poitevin G, Grosjean S, Latger-Cannard V, Devaux Y, Zannad F, Regnault V, Lacolley P, Mertes PM, Hess K, Longrois D (2008) C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor α, on human monocytes. Thromb Haemost 99: 558-569.
• Hattori Y, Matsumura M, Kasai K (2003) Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 58: 186-195.
• Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349: 462-466.
• Heuertz RM, Schneider GP, Potempa LA, Webster RO (2005) Native and modified C-reactive protein bind different receptors on human neutrophils. Int J Biochem Cell Biol 37: 320-335.
• Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB (2005) Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 102: 8309-8314.
• Hurlimann J, Thorbecke GJ, Hochwald GM (1966) The liver as the site of C-reactive protein formation. J Exp Med 123: 365-378.
• Jabs WJ, Logering BA, Gerke P, Kreft B, Wolber EM, Klinger MH, Fricke L, Steinhoff J (2003) The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol 33: 152-161.
• Ji SR, Wu Y, Potempa LA, Qiu Q, Zhao J (2006a) Interactions of C-reactive protein with low-density lipoproteins: Implications for an active role of modified C-reactive protein in atherosclerosis. Int J Biochem Cell Biol 38: 648-661.
• Ji SR, Wu Y, Potempa LA, Liang YH, Zhao J (2006b) Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 26: 935-941.
• Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, Lu W, Zhao J (2007) Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRPm. FASEB J 21: 284-294.
• Jiang HX, Siegel JN, Gewurz H (1991) Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J Immunol 146: 2324-2330.
• Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, Keaney JF Jr, Wilson PW, Newton-Cheh C, Musone SL, Camargo AL, Drake JA, Levy D, O'Donnell CJ, Hirschhorn JN, Benjamin EJ (2006) Contribution of clinical correlates and 13C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 113: 1415-1423.
• Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Saito T, Manabe I, Imai Y, Nagai R (2006) C-reactive protein induces VCAM-1 gene expression through NF-κB activation in vascular endothelial cells. Atherosclerosis 185: 39-46.
• Kew RR, Hyers TM, Webster RO (1990) Human C-reactive protein inhibits neutrophil chemotaxis in vitro: possible implications for the adult respiratory distress syndrome. J Lab Clin Med 115: 339-345.
• Khreiss T, Jozsef L, Hossain S, Chan JS, Potempa LA, Filep JG (2002a) Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. J Biol Chem 277: 40775-40781.
• Khreiss T, Jozsef L, Potempa LA, Filep JG (2002b) Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res 97: 690-697.
• Khreiss T, Jozsef L, Potempa LA, Filep JG (2004a) Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109: 2016-2022.
• Khreiss T, Jozsef L, Potempa LA, Filep JG (2004b) Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation 110: 2713-2720.
• Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB (1999) C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237-242.
• Kovacs A, Green F, Hansson LO, Lundman P, Samnegard A, Boquist S, Ericsson CG, Watkins H, Hamsten A, Tornvall P (2005) A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 178: 193-198.
• Kovacs A, Tornvall P, Nilsson R, Tegner J, Hamsten A, Bjorkegren J (2007) Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA 104: 13768-13773.
• Kresl JJ, Potempa LA, Anderson BE (1998) Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. Int J Biochem Cell Biol 30: 1415-1426.
• Kresl JJ, Potempa LA, Anderson B, Radosevich JA (1999) Inhibition of mouse mammary adenocarcinoma (EMT6) growth and metastases in mice by a modified form of C-reactive protein. Tumour Biol 20: 72-87.
• Lafuente N, Azcutia V, Matesanz N, Cercas E, Rodriguez-Manas L, Sanchez-Ferrer CF, Peiro C (2005) Evidence for sodium azide as an artifact mediating the modulation of inducible nitric oxide synthase by C-reactive protein. J Cardiovasc Pharmacol 45: 193-196.
• Li L, Roumeliotis N, Sawamura T, Renier G (2004) C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 95: 877-883.
• Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331: 417-424.
• Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW (1995) C-reactive protein binds to FcγRI in transfected COS cells. J Immunol 155: 2185-2193.
• Marumo T, Schini-Kerth VB, Fisslthaler B, Busse R (1997) Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-κB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation 96: 2361-2367.
• McGrath FD, Brouwer MC, Arlaud GJ, Daha MR, Hack CE, Roos A (2006) Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J Immunol 176: 2950-2957.
• Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292: C82-C97.
• Mine S, Fujisaki T, Suematsu M, Tanaka Y (2001) Activated platelets and endothelial cell interaction with neutrophils under flow conditions. Intern Med 40: 1085-1092.
• Muller H, Fehr J (1986) Binding of C-reactive protein to human polymorphonuclear leukocytes: evidence for association of binding sites with Fc receptors. J Immunol 136: 2202-2207.
• Nilsson J (2005) CRP - marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol 25: 1527-1528.
• Nunomura W, Hatakeyama M (1990) Binding of low density lipoprotein (LDL) to C-reactive protein (CRP): a possible binding through apolipoprotein B in LDL at phosphorylcholine-binding site of CRP. Hokkaido Igaku Zasshi 65: 474-480.
• Osmand AP, Friedenson B, Gewurz H, Painter RH, Hofmann T, Shelton E (1977) Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci USA 74: 739-743.
• Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-2168.
• Pasceri V, Cheng JS, Willerson JT, Yeh ET (2001) Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103: 2531-2534.
• Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L (2004) C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109: 647-655.
• Pepys MB (1981) C-reactive protein fifty years on. Lancet 1: 653-657.
• Pepys MB (2005) CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 25: 1091-1094.
• Pepys MB (2008) C-reactive protein is neither a marker nor a mediator of atherosclerosis. Nat Clin Pract Nephrol 4: 234-235.
• Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, Sabin CA, Zychlinsky A, de Diego J (2005) Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 97: e97-e103.
• Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440: 1217-1221.
• Perkins SJ, Nealis AS, Sutton BJ, Feinstein A (1991) Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. J Mol Biol 221: 1345-1366.
• Potempa LA, Maldonado BA, Laurent P, Zemel ES, Gewurz H (1983) Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol Immunol 20: 1165-1175.
• Potempa LA, Siegel JN, Fiedel BA, Potempa RT, Gewurz H (1987) Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Mol Immunol 24: 531-541.
• Potempa LA, Motie M, Wright KE, Crump BL, Radosevich JA, Sakai N, Lai G, Tanaka K, Kojima E, Tsuboi A (1996) Stimulation of megakaryocytopoiesis in mice by human modified C-reactive protein (mCRP). Exp Hematol 24: 258-264.
• Ramage L, Proudfoot L, Guy K (2004) Expression of C-reactive protein in human lung epithelial cells and upregulation by cytokines and carbon particles. Inhal Toxicol 16: 607-613.
• Reifenberg K, Lehr HA, Baskal D, Wiese E, Schaefer SC, Black S, Samols D, Torzewski M, Lackner KJ, Husmann M, Blettner M, Bhakdi S (2005) Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol 25: 1641-1646.
• Reitz C, Berger K, de Maat MP, Stoll M, Friedrichs F, Kardys I, Witteman JC, Breteler MM (2007) CRP gene haplotypes, serum CRP, and cerebral small-vessel disease: the Rotterdam Scan Study and the MEMO Study. Stroke 38: 2356-2359.
• Ridker PM (2002a) Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. Circulation 105: 2583-2585.
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979.
• Ridker PM, Hennekens CH, Buring JE, Rifai N (2000a) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843.
• Ridker PM, Rifai N, Stampfer MJ, Hennekens CH (2000b) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101: 1767-1772.
• Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285: 2481-2485.
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002b) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565.
• Ridker PM, Buring JE, Cook NR, Rifai N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107: 391-397.
• Saeland E, van Royen A, Hendriksen K, Vile-Weekhout H, Rijkers GT, Sanders LA, van de Winkel JG (2001) Human C-reactive protein does not bind to FcγRIIa on phagocytic cells. J Clin Invest 107: 641-643.
• Salonen EM, Vartio T, Hedman K, Vaheri A (1984) Binding of fibronectin by the acute phase reactant C-reactive protein. J Biol Chem 259: 1496-1501.
• Santoso S, Sachs UJ, Kroll H, Linder M, Ruf A, Preissner KT, Chavakis T (2002) The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med 196: 679-691.
• Saxena U, Nagpurkar A, Dolphin PJ, Mookerjea S (1987) A study on the selective binding of apoprotein B- and E-containing human plasma lipoproteins to immobilized rat serum phosphorylcholine-binding protein. J Biol Chem 262: 3011-3016.
• Schwedler SB, Guderian F, Dammrich J, Potempa LA, Wanner C (2003) Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant 18: 2300-2307.
• Schwedler SB, Amann K, Wernicke K, Krebs A, Nauck M, Wanner C, Potempa LA, Galle J (2005) Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 112: 1016-1023.
• Schwedler SB, Kuhlencordt PJ, Ponnuswamy PP, Hatiboglu G, Quaschning T, Widder J, Wanner C, Potempa LA, Galle J (2007) Native C-reactive protein induces endothelial dysfunction in ApoE-/- mice: implications for iNOS and reactive oxygen species. Atherosclerosis 195: e76-e84.
• Scirica BM, Morrow DA (2006) Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 113: 2128-2134.
• Shantsila E, Watson T, Lip GY (2007) Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 49: 741-752.
• Shrive AK, Cheetham GM, Holden D, Myles DA, Turnell WG, Volanakis JE, Pepys MB, Bloomer AC, Greenhough TJ (1996) Three dimensional structure of human C-reactive protein. Nat Struct Biol 3: 346-354.
• Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, Ballantyne CM, Zhang L, Furman MI, Berndt MC, Lopez JA (2000) Platelet glycoprotein Ibα is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 192: 193-204.
• Singh U, Devaraj S, Jialal I (2005) C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 25: 2216-2221.
• Singh SK, Suresh MV, Prayther DC, Moorman JP, Rusinol AE, Agrawal A (2008a) C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells. J Immunol 180: 4316-4322.
• Singh SK, Suresh MV, Prayther DC, Moorman JP, Rusinol AE, Agrawal A (2008b) Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum. Clin Chim Acta 394: 94-98.
• Singh SK, Suresh MV, Voleti B, Agrawal A (2008c) The connection between C-reactive protein and atherosclerosis. Ann Med 40: 110-120.
• Stein MP, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C, Du Clos TW (2000) C-reactive protein binding to FcγRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest 105: 369-376.
• Suh W, Kim KL, Choi JH, Lee YS, Lee JY, Kim JM, Jang HS, Shin IS, Lee JS, Byun J, Jeon ES, Kim DK (2004) C-reactive protein impairs angiogenic functions and decreases the secretion of arteriogenic chemo-cytokines in human endothelial progenitor cells. Biochem Biophys Res Commun 321: 65-71.
• Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, Chen YE, Fan J (2005) C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol 167: 1139-1148.
• Suresh MV, Singh SK, Ferguson DA Jr, Agrawal A (2006) Role of the property of C-reactive protein to activate the classical pathway of complement in protecting mice from pneumococcal infection. J Immunol 176: 4369-4374.
• Swafford AN Jr, Bratz IN, Knudson JD, Rogers PA, Timmerman JM, Tune JD, Dick GM (2005) C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am J Physiol Heart Circ Physiol 288: H1786-H1795.
• Swanson SJ, McPeek MM, Mortensen RF (1989) Characteristics of the binding of human C-reactive protein (CRP) to laminin. J Cell Biochem 40: 121-132.
• Szalai AJ, McCrory MA (2002) Varied biologic functions of C-reactive protein: lessons learned from transgenic mice. Immunol Res 26: 279-287.
• Taskinen S, Kovanen PT, Jarva H, Meri S, Pentikainen MO (2002) Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. Biochem J 367: 403-412.
• Taylor KE, Giddings JC, van den Berg CW (2005) C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 25: 1225-1230.
• Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J, Sabin CA, Dhillon AP, Pepys MB (2008) Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis 196: 248-255.
• Thurberg BL, Collins T (1998) The nuclear factor kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 9: 387-396.
• Tillett WS, Francis T Jr (1930) Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 52: 561-571.
• Torzewski J (2005) C-reactive protein and atherogenesis: new insights from established animal models. Am J Pathol 167: 923-925.
• Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V (1998) C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18: 1386-1392.
• Trion A, de Maat MP, Jukema JW, van der Laarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HM, Emeis JJ (2005) No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol 25: 1635-1640.
• Tseng J, Mortensen RF (1988) Binding of human C-reactive protein (CRP) to plasma fibronectin occurs via the phosphorylcholine-binding site. Mol Immunol 25: 679-686.
• Vaith P, Potempa LA (2000) Deposition of modified or native C-reactive protein in atherosclerotic arteries? Arterioscler Thromb Vasc Biol 20: 1173-1174.
• van den Berg CW, Taylor KE, Lang D (2004) C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol 24: e168-e171.
• van Tits L, de Graaf J, Toenhake H, van Heerde W, Stalenhoef A (2005) C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 25: 717-722.
• Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I (2002) Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106: 1439-1441.
• Venugopal SK, Devaraj S, Jialal I (2003) C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 108: 1676-1678.
• Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA (2002a) Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105: 1890-1896.
• Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ (2002b) A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106: 913-919.
• Verma S, Badiwala MV, Weisel RD, Li SH, Wang CH, Fedak PW, Li RK, Mickle DA (2003) C-reactive protein activates the nuclear factor-κB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 126: 1886-1891.
• Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ (2004a) C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109: 2058-2067.
• Verma S, Szmitko PE, Yeh ET (2004b) C-reactive protein: structure affects function. Circulation 109: 1914-1917.
• Verma S, Devaraj S, Jialal I (2006) Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 113: 2135-2150.
• Vlaicu R, Rus HG, Niculescu F, Cristea A (1985) Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis 55: 35-50.
• Volanakis JE, Wirtz KW (1979) Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature 281: 155-157.
• Voleti B, Agrawal A (2006) Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Mol Immunol 43: 891-896.
• Wang HW, Sui SF (2001) Dissociation and subunit rearrangement of membrane-bound human C-reactive proteins. Biochem Biophys Res Commun 288: 75-79.
• Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S (2003) C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107: 1783-1790.
• Wang Q, Hunt SC, Xu Q, Chen YE, Province MA, Eckfeldt JH, Pankow JS, Song Q (2006) Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI Family Heart Study. Am J Physiol Heart Circ Physiol 291: H2752-H2757.
• Whisler RL, Proctor VK, Downs EC, Mortensen RF (1986) Modulation of human monocyte chemotaxis and procoagulant activity by human C-reactive protein (CRP). Lymphokine Res 5: 223-228.
• Whitehead AS, Bruns GA, Markham AF, Colten HR, Woods DE (1983) Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1. Science 221: 69-71.
• Woollard KJ, Phillips DC, Griffiths HR (2002) Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin Exp Immunol 130: 256-262.
• Xie L, Chang L, Guan Y, Wang X (2005) C-reactive protein augments interleukin-8 secretion in human peripheral blood monocytes. J Cardiovasc Pharmacol 46: 690-696.
• Yap SH, Moshage HJ, Hazenberg BP, Roelofs HM, Bijzet J, Limburg PC, Aarden LA, van Rijswijk MH (1991) Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta 1091: 405-408.
• Yaron G, Brill A, Dashevsky O, Yosef-Levi IM, Grad E, Danenberg HD, Varon D (2006) C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br J Haematol 134: 426-431.
• Yasojima K, Schwab C, McGeer EG, McGeer PL (2000) Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 887: 80-89.
• Yasojima K, Schwab C, McGeer EG, McGeer PL (2001) Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158: 1039-1051.
• Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG (2008) Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359: 1897-1908.
• Zeller JM, Sullivan BL (1992) C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by IgG-stimulated monocytes and neutrophils. J Leukoc Biol 52: 449-455.
• Zouki C, Haas B, Chan JS, Potempa LA, Filep JG (2001) Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. J Immunol 167: 5355-5361.